Upma Sharma

Upma Sharma is President of Arsenal Medical. Arsenal is a clinical stage company focused on in situ forming biomaterials platform to create customized mechanical implants in the body. Dr. Sharma has led Arsenal’s lead product, ResQFoam, from invention to the clinic, including management of the product development process, establishment of GMP contract manufacturing, and receipt of a FDA IDE approval. Previously, at Lyra Therapeutics, Dr. Sharma advanced the company’s innovative drug delivery depot from concept through a Phase I clinical study. Under Dr. Sharma’s leadership, Arsenal Medical and Lyra Therapeutics have been awarded more than $50M in government funding to support product development efforts. Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Dr. Sharma was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.